16.94 USD
↘ 0.04 (0.24%)AT CLOSE (AS OF 04:15 PM EDT)
Theravance Biopharma, Inc.
TBPHNASDAQ • USD
Market: CLOSED
Theravance Biopharma, Inc. (TBPH) trades at $16.94 per share. Technicals currently rate "Neutral" while our fundamental analysis reads "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (39.4%) and a bearish Death Cross on the long-term moving averages. Valuation metrics place TBPH at a fair price relative to peers.
Technical & fundamental data as of Jul 17, 2026.
Open?$16.97
High?$16.99
Low?$16.93
Prev. Close?$16.97
Volume?449.5K
Avg. Volume?743.8K
VWAP?$16.95
Rel. Volume?0.60x
Bid / Ask
Bid?$14.53 × 100
Ask?$19.37 × 100
Spread?$4.84
Midpoint?$16.95
Valuation & Ratios
Market Cap?879.5M
Shares Out?51.6M
Float?47.2M
Float %?91.5%
P/E Ratio?7.68
P/B Ratio?3.03
EPS?$2.21
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Themes
Employees
90
Market Cap
879.5M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-05-16
Address
UGLAND HOUSE, SOUTH CHURCH STREET
GEORGE TOWN, GRAND CAYMAN, CA KY1-1104
Phone: 650-808-6000
GEORGE TOWN, GRAND CAYMAN, CA KY1-1104
Phone: 650-808-6000
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?20
Momentum?50
Short Sent.?65
Piotroski F-Score?3/9Weak
Altman Z-Score?1.48Distress
Confidence?64%Moderate
Short InterestElevated
Short % of Float?9.55%Elevated
Short Interest?4.5M
Days to Cover?4.2
Free Float47.2M
Avg Daily Volume1.1M
Settlement Date2026-06-30
Financial Health
Current Ratio?6.47Strong
Quick Ratio?6.47Strong
Cash Ratio?4.46Strong
Debt/Equity?0.01Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?7.7CHEAP▾
Peers100
S&P97
P/B?3.03FAIR▾
Peers100
S&P55
P/S?8.01HIGH▾
Peers100
S&P13
P/FCF?3.3CHEAP▾
Peers100
S&P97
EV/EBITDA?90.3HIGH▾
Peers100
S&P3
EV/Sales?5.41FAIR▾
Peers100
S&P33
Returns & Efficiency
ROE?39.4%STRONG▾
Peers50
S&P87
ROA?24.3%STRONG▾
Peers50
S&P97
Cash Flow & Enterprise
FCF?$268.7M
Enterprise Value?$593.8M
Fundamentals ratios updated end of day